Mimetogen Pharmaceuticals Inc. announced that it has appointed Kim Brazzell, PhD as chief medical officer.
Brazzell will lead the development of Mimetogen’s MIM-D3 program for the treatment of dry eye. The company previously announced in June of 2011 that MIM-D3, a small molecule TrkA agonist, had successfully completed a 150-patient, multi-center Phase 2 trial for the treatment of dry eye.
Release Date: Jan. 5, 2012
Source: Mimetogen Pharmaceuticals Inc.
